.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin caused enhanced progression-free and also general survival, resulting in FDA approval and also a new therapy option for people.